Tagged with Teva,

Latvia The top 20 companies in the Latvian pharmaceutical market for 2017, sorted by total value and market share, with data on year-on-year growth. American giant AbbVie ranks first, with an almost six percent market share and astounding 65 percent year-on-year growth, followed by TEVA and Sanofi.

Baltics Janis Meiksans, general manager at TEVA Baltics, explains how the base of the company’s success is what they call ‘generic evangelism’ and how from being a marketing and distribution organization in the region, they successfully managed to rank number one pharmaceutical company by sales. Janis, can you talk our international…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Lithuania Audrius Tutlys, country manager at Teva Lithuania, highlights the importance of Teva in Lithuania, based not only on its broad product offering but also its manufacturing capabilities and shares his willingness to position Teva as a true partner of the government in making Lithuania a European biotech center. Can you…

Canada Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and the critical importance of Canada possessing a local pharma manufacturing industry. Teva recently announced a new global CEO, Kåre Schultz.…

Bulgaria Nikolay Hadjidontchev, general manager at Actavis EAD – a Teva company (the sales and marketing part of the company) in Bulgaria, explains the importance of finding the right balance between innovative and generic portfolios and highlights the unique positioning of Teva in Bulgaria as a consequence of the global acquisition…

Ukraine Dmytro Spitsyn, General Manager of Teva Ukraine, which proudly stands as the largest international company operating in the country, documents the challenges he faced and the strategies he implemented to overcome the 2013 crisis in Ukraine, while Teva has been positioning itself as a company committed to increasing life expectancy…

Singapore Teva’s recently appointed SVP of APAC and MENA Vivek Bachhawat details his relatively seamless journey from Actavis to Teva and the synergies inherent in both organizations even prior to the merger. He also highlights the company’s continued commitment to Singapore and its key regional role which will grow in importance…

Generics Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It has been five years since the merger of Teva and Mepha in Switzerland, and curiously the brand name Mepha remains in…

Czech Republic A current lack of transparency in Czech healthcare spending is severely detrimental to all industry stakeholders. However, new synergies between the private and public sectors are helping to clear these murky waters.   The Czech Republic, with a population of about 10.5 million, is the third most populous country within Central…

Pharma Teva Czech Republic & Slovakia GM Juan Carlos Conde describes how the Czech Republic hosts Teva’s third largest manufacturing site within Europe and the recent implementation of a more efficient cluster organization covering the Czech and Slovakian markets. You became general manager of Teva Pharmaceuticals Czech Republic & Slovakia eight…

Pharma Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in the Netherlands and your global ambitions, a truly ambitious culture emanates from TEVA’s achievements. Where does this drive come from?…